JP6672296B2 - 強力なγ−セクレターゼモジュレータ - Google Patents

強力なγ−セクレターゼモジュレータ Download PDF

Info

Publication number
JP6672296B2
JP6672296B2 JP2017523912A JP2017523912A JP6672296B2 JP 6672296 B2 JP6672296 B2 JP 6672296B2 JP 2017523912 A JP2017523912 A JP 2017523912A JP 2017523912 A JP2017523912 A JP 2017523912A JP 6672296 B2 JP6672296 B2 JP 6672296B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533237A5 (enExample
JP2017533237A (ja
Inventor
エル． ワグナー，スティーブン
エル． ワグナー，スティーブン
シー． モブリー，ウィリアム
シー． モブリー，ウィリアム
イー． タンシ，ラドルフ
イー． タンシ，ラドルフ
ジョンソン，グラハム
バックル，ロナルド
メイヒュー，ニコラス
ジェイソン ハー，ロバート
ジェイソン ハー，ロバート
ディー． ラインアーソン，ケヴィン
ディー． ラインアーソン，ケヴィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017533237A publication Critical patent/JP2017533237A/ja
Publication of JP2017533237A5 publication Critical patent/JP2017533237A5/ja
Application granted granted Critical
Publication of JP6672296B2 publication Critical patent/JP6672296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017523912A 2014-10-31 2015-10-30 強力なγ−セクレターゼモジュレータ Active JP6672296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073553P 2014-10-31 2014-10-31
US62/073,553 2014-10-31
PCT/US2015/058429 WO2016070107A1 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Publications (3)

Publication Number Publication Date
JP2017533237A JP2017533237A (ja) 2017-11-09
JP2017533237A5 JP2017533237A5 (enExample) 2018-12-06
JP6672296B2 true JP6672296B2 (ja) 2020-03-25

Family

ID=55858421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523912A Active JP6672296B2 (ja) 2014-10-31 2015-10-30 強力なγ−セクレターゼモジュレータ

Country Status (8)

Country Link
US (2) US10472346B2 (enExample)
EP (1) EP3212633B1 (enExample)
JP (1) JP6672296B2 (enExample)
CN (1) CN107406423B (enExample)
AU (1) AU2015338946B2 (enExample)
CA (1) CA2966423C (enExample)
MX (1) MX381224B (enExample)
WO (1) WO2016070107A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212633B1 (en) 2014-10-31 2019-12-04 The General Hospital Corporation Potent gamma-secretase modulators
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020231977A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
EP4396177A1 (en) * 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
EP0968711B9 (en) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Dermatological patch sheet and process for producing base sheet therefor
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
JP4762250B2 (ja) 2004-12-09 2011-08-31 エフ．ホフマン−ラ ロシュ アーゲー フェニル−ピペラジンメタノン誘導体
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2004625B1 (en) 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
US8410142B2 (en) 2007-03-02 2013-04-02 Merck Sharp & Dohme Corp. Bipyridine carboxamide orexin receptor antagonists
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
EP2401276B1 (en) 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
NZ597505A (en) 2009-07-15 2013-05-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
WO2011120026A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Pyrazolyl-pyrimidines as kinase inhibitors
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
EP3212633B1 (en) 2014-10-31 2019-12-04 The General Hospital Corporation Potent gamma-secretase modulators

Also Published As

Publication number Publication date
EP3212633A1 (en) 2017-09-06
EP3212633A4 (en) 2018-07-25
WO2016070107A1 (en) 2016-05-06
CA2966423C (en) 2023-10-24
MX2017005715A (es) 2018-02-23
CA2966423A1 (en) 2016-05-06
MX381224B (es) 2025-03-12
BR112017009010A2 (pt) 2017-12-26
AU2015338946A1 (en) 2017-06-15
US10472346B2 (en) 2019-11-12
CN107406423A (zh) 2017-11-28
US11117884B2 (en) 2021-09-14
JP2017533237A (ja) 2017-11-09
US20200055840A1 (en) 2020-02-20
US20180093967A1 (en) 2018-04-05
AU2015338946B2 (en) 2020-06-11
CN107406423B (zh) 2020-06-16
EP3212633B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
JP6672296B2 (ja) 強力なγ−セクレターゼモジュレータ
CN107428719B (zh) 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
JP6800013B2 (ja) 重水素化２，４−チアゾリジンジオン及び治療方法
WO2003074525A1 (fr) Compose heterocyclique azote
JP7470046B2 (ja) ６－アミノイソキノリンのモノ酸塩及びその使用
WO2015085238A1 (en) Inhibitors of lpxc
JP2006501243A (ja) グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター
JPWO2006001318A1 (ja) スルホンアミド化合物
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
CN113365982A (zh) 酰胺二取代的吡啶或哒嗪化合物
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
TWI400238B (zh) ２－酮基烷基－１－哌－２－酮衍生物、其製備及其治療用途
JP6310923B2 (ja) ジヒドロピリミジン誘導体の結晶形
JP6302937B2 (ja) ２−（（１ｒ，４ｒ）−４−（４−（５−（ベンゾオキサゾール−２−イルアミノ）ピリジン−２−イル）フェニル）シクロヘキシル）酢酸のメグルミン塩形態、およびｄｇａｔ１阻害剤としてのそれらの使用
CN111372579A (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
JP7025542B2 (ja) Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
BR112017009010B1 (pt) MODULADORES POTENTES DE GAMA-SECRETASE, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA REDUZIR O NÍVEL DE UMA ALOFORMA DE PEPTÍDEO Aß EM UMA CÉLULA E PRÓ-FÁRMACO
CN116531373B (zh) 噻唑类化合物、其药物组合物及应用
WO2019179362A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
TW202321206A (zh) 轉甲狀腺素蛋白穩定化合物
CN118852111A (zh) 一种哌啶基吲哚化合物的晶型及其制备方法
US20020147218A1 (en) Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
JP2011231050A (ja) Ｎｐｙｙ５受容体拮抗作用を有するヘテロ環化合物
AU2002222407A1 (en) Ethanolates of sodium-hydrogen exchanger type-1 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250